Published: February 2026 | Last updated: May 2026
A British father who nearly lost his tongue to cancer is urging other men to pay closer attention to HPV. His story, reported by BBC News, broke the old script for head and neck cancer: no decades of smoking, no advanced age, just a routine-seeming life in his late thirties interrupted by a virus most men never think about.
This article walks through what oral HPV means for men today: how the virus reaches the throat, which symptoms warrant attention, what testing options actually exist (and which do not), and where vaccination still fits even for adults who missed it the first time. It also addresses the at-home testing question honestly, because the answer is less convenient than many sites suggest.
How HPV Reaches the Throat (and Stays Quiet)
Human papillomavirus is common enough that the CDC estimates nearly every sexually active adult will get at least one strain at some point in their lives. In most cases, the immune system clears the infection within one to two years, often without any symptoms at all. The person never knows it happened.
The problem is that not every strain leaves. Around a dozen high-risk types can persist in the deeper tissue of the throat, tonsils, and base of the tongue. Years later, the cells in that tissue may begin to change. According to the CDC, HPV is thought to cause between 60 and 70 percent of oropharyngeal cancers in the United States.
Transmission happens through intimate skin-to-skin and mucosal contact, which includes oral sex. The exposure pattern that matters is proximity over time rather than partner count or any particular behavior. There is rarely an obvious moment to point to.
Of the roughly 200 known HPV types, only about a dozen are classified as high-risk for cancer. HPV-16 alone accounts for the large majority of HPV-related oropharyngeal cancers, far more than any other strain in this category. That is why HPV-16 is the type most often referenced in oral-cancer prevention research and why the current 9-valent HPV vaccine (Gardasil 9) includes HPV-16 protection.
Symptoms Most Men Overlook
The trickiest part of HPV-related throat cancer is how late the warning signs show up. Most oral HPV infections cause nothing detectable. Even when high-risk strains persist for years, the cellular changes happening in deeper tissue rarely produce sensations until they reach a certain size or location. By the time something feels off, the change may have been underway for a long time.
The father in the BBC story described a small sore that simply would not heal. Other patients describe persistent hoarseness, a lump in the neck that does not go away, pain when swallowing, or a sense of something stuck in the throat. None of these symptoms shout cancer. Most have benign explanations, which is exactly why they get dismissed.
Two weeks is the cutoff most clinicians use before they want to see the patient in person. A dentist visit is often the easiest place to start because dentists already examine the oral cavity on routine cleanings.
| Early Warning Sign | What It Might Feel Like | When to Seek Evaluation |
|---|---|---|
| Persistent mouth sore | A small ulcer on the tongue or inside the cheek that does not heal | If it lasts more than two weeks |
| Difficulty swallowing | Food feels like it sticks in the throat | If ongoing or worsening over two weeks |
| Unexplained hoarseness | Voice changes without a cold or recent strain | If lasting over two weeks |
| Painless neck lump | Firm swelling under the jaw or on the side of the neck | Promptly, even without other symptoms |
| Persistent ear pain on one side | Dull ache referred from the throat with no ear infection | If lasting over two weeks |
Why There Is No Routine HPV Test for Men
This is where many men get tripped up. Women have Pap and HPV co-testing, a long-established screening pathway that catches cervical cell changes linked to HPV early enough for intervention. There is no equivalent routine screening for the throat, mouth, or penis in primary care. The U.S. FDA has not approved any test for oral HPV screening in asymptomatic men, and no major guideline body recommends one.
That gap exists for a few reasons. Oral HPV infections are common, transient in most cases, and not predictive of cancer on a one-to-one basis. Testing every man and finding the virus in the saliva of millions would not tell anyone which men are heading toward cancer and which are clearing the infection silently. The clinical action is unclear, and false alarms could drive a great deal of unnecessary worry and intervention.
'No routine screening' does not mean 'no test at all.' Three narrower contexts use HPV testing today:
- Anal HPV screening: offered to some high-risk patient groups, including men who have sex with men and people living with HIV, by their specialists.
- Biopsy of visible lesions: a suspicious lesion in the mouth or genital area can be biopsied and tested for HPV markers to inform treatment.
- Research-setting oral rinse studies: epidemiology teams use oral rinse samples to track population-level prevalence, not to give clinical results to individuals.
None of these is a general-population screening tool a man can request at a primary care visit.
Where At-Home Testing Fits (and Where It Doesn't)
No at-home kit screens for oral HPV cancer in men. Anyone selling one is overpromising. Our rapid HPV swab on this site is validated for vaginal self-collection in women only; it does not detect oral or pharyngeal infection in any gender, and it does not predict cancer.
At-home STI testing still plays a real role in this conversation though. HPV rarely travels alone. Men who report having had unprotected oral sex are statistically more likely to have been exposed to other infections at the same time, including chlamydia, gonorrhea, syphilis, and HIV. Catching any of those changes treatment and protects partners. Building a habit of periodic at-home screening for the infections that do have reliable tests is one practical way to stay engaged with sexual health between clinic visits.
HPV Vaccination: Still Useful for Many Adult Men
The HPV vaccine has dramatically reduced infections from the high-risk strains it targets. In the United States, the CDC and ACIP recommend routine vaccination starting around ages 11 to 12, with catch-up vaccination through age 26. The vaccine is also approved for adults aged 27 through 45 under a shared clinical decision-making framework, which means it is worth a conversation with a provider even past the routine window.
For many men in their thirties, forties, and early fifties, this option simply never came up. Vaccination programs initially focused on adolescent girls, and male enrollment lagged for years afterward. The father in the BBC story almost certainly grew up before any boys-eligible HPV vaccination program existed in his country. That generational gap is part of why HPV-related oropharyngeal cancers continue to rise in middle-aged men even as vaccination rates climb in younger cohorts.
One important caveat: vaccination after exposure does not treat or clear existing HPV infections. It cannot undo cellular damage already in progress. What it can do is protect against high-risk strains a person has not yet encountered, which can still meaningfully reduce long-term risk. Out-of-pocket cost in the U.S. without insurance runs roughly $250 per dose for the recommended three-dose adult series, which is part of the decision-making math.
| Prevention Strategy | How It Helps | Who Benefits Most |
|---|---|---|
| HPV vaccination (Gardasil 9) | Prevents infection from high-risk strains that drive most HPV-related cancers | Preteens and teens routinely; adults through 26 for catch-up; ages 27 to 45 case-by-case with a provider |
| Barrier protection during oral sex | Reduces but does not eliminate HPV transmission risk | Sexually active adults, particularly with new or multiple partners |
| Symptom awareness using the two-week rule | Catches potential HPV-related cancers earlier when treatment is less invasive | All adults, especially men over 40 with any oral or throat symptom |
| Routine STI testing for related infections | Detects co-occurring infections that share oral transmission routes | Anyone with new or multiple partners; people who have not been screened recently |
Why Men Delay Care, and Why It Changes Outcomes
There is a cultural pattern worth naming here. Many men are socialized to minimize bodily symptoms, to power through, to wait until something becomes undeniable before seeking care. A small sore on the tongue feels easy to dismiss. A lump in the neck might be attributed to a knot in a lymph node from a recent cold. Work continues. Appointments get pushed. Months pass.
The father in the BBC report did not ignore his symptom forever. He eventually sought evaluation, which is why he still has a tongue. The point of his public campaign is that the delay between noticing and acting was longer than it needed to be, and the same pattern shows up in many men diagnosed with HPV-related oropharyngeal cancer. Earlier stages respond well to less aggressive treatment. Later stages may require partial tongue removal, neck dissection, radiation, and chemotherapy, with significant impact on speech, swallowing, and quality of life.
A dental soft-tissue exam typically takes about 30 minutes and is usually covered under routine dental visits. That is the practical starting point for any mouth or throat symptom that has lingered past two weeks.
Understanding Risk Without Shame
One reason men avoid this conversation is the embarrassment baked into anything labeled an STI. HPV is one of the most common sexually transmitted viruses on the planet. Someone can have a single lifetime partner and still contract it. Someone else can have many partners and never develop a complication. The connection between exposure history and outcome reflects which strains a person encountered, how long their immune system took to handle them, and how genetic and lifestyle factors shaped the response, rather than any moral calculation.
Shame keeps people away from clinics. Men who feel judged by the testing conversation skip it. Men who fear what a diagnosis means for their relationship or self-image find reasons to wait. ACIP has revised its guidance three times since 2016 specifically to broaden men's HPV vaccine eligibility, reflecting the same shift in framing inside the public-health field.
HPV is so common that almost every person who is sexually active will get HPV at some time in their life if they don't get the HPV vaccine.
From Infection to Disease: The Long Timeline
One of the more disorienting aspects of HPV-related cancers is how disconnected the diagnosis can feel from any recognizable cause. The infection that eventually leads to cellular changes may have happened ten, twenty, or even thirty years before symptoms appear. By that point, tracing it back to a specific partner or moment is usually impossible, and trying to do so tends to create pain without insight.
It helps to separate two things: infection and disease. Infection is the presence of the virus in tissue. Disease is the consequence of long-term cellular change that some persistent infections eventually cause. Most men with persistent oral HPV will never develop cancer at all.
| Stage | What Is Happening Biologically | What You Might Notice |
|---|---|---|
| Initial infection | HPV enters epithelial cells through intimate contact | Usually nothing at all |
| Immune clearance | Body suppresses or eliminates virus within one to two years | No symptoms in most cases |
| Persistent infection | High-risk strain remains active in throat tissue for years | Still often no symptoms |
| Cellular changes | Abnormal growth patterns begin in tonsils, base of tongue, or pharynx | Subtle soreness, hoarseness, or mild discomfort |
| Visible tumor formation | Abnormal cells cluster into a detectable mass | Non-healing sore, neck lump, difficulty swallowing |
The Quiet Rise of HPV Oral Cancers in Men
Over the past two decades, HPV-related oropharyngeal cancers have climbed steadily in high-income countries, and the demographic profile has shifted. CDC surveillance data put oral HPV prevalence at roughly 10 percent in men compared with 3.6 percent in women, and most U.S. oropharyngeal cancer cases are now linked to HPV rather than tobacco or alcohol exposure.
The patient profile has changed accordingly. Where head and neck cancer once primarily appeared in older men with long smoking histories, HPV-driven cases more often show up in non-smokers, sometimes in their forties or even thirties. The BBC father fits that newer pattern. He did not match the textbook risk profile in the traditional sense, which is part of what made his diagnosis so jarring for him and for readers.
HPV-positive oropharyngeal cancers caught at early stages have meaningfully better outcomes than the same cancers found late, and they generally respond better to treatment than HPV-negative cases at comparable stages. The gap widens as stage increases.
What You Can Do This Week
Vigilance and fear are different things in practice. Fear runs worst-case scenarios at 2 a.m. after reading a news story. Vigilance is a short list of small, concrete steps that can be handled in a week and then largely forgotten.
If you are under 45 and never received the HPV vaccine, ask your primary care provider or pharmacist whether it makes sense for you. The conversation costs nothing. If you are sexually active with new or multiple partners, build a routine of STI screening that includes the infections you can actually test for at home or at a clinic, every six to twelve months depending on exposure patterns. If you have noticed any mouth or throat symptom that has been present for two weeks without improving, schedule an evaluation now rather than next month.
The easiest place to flag a persistent mouth or throat symptom is a routine dental cleaning, since dentists already examine the oral cavity twice a year as a matter of course.
According to <a href="https://www.cdc.gov/hpv/about/cancers-caused-by-hpv.html" target="_blank" rel="noopener">the CDC, HPV vaccination can prevent over 90 percent of cancers caused by HPV</a> when given at the recommended ages. That includes most cancers of the cervix, anus, penis, vulva, vagina, and the back of the throat. The vaccine works prophylactically rather than therapeutically, which is why earlier vaccination delivers the strongest protection.
FAQs
- Can men get an at-home test for oral HPV?
- Not for oral HPV specifically. No FDA-approved at-home oral HPV cancer screening test exists for men, and our HPV swab on this site is validated for vaginal self-collection in women only. What men can do is stay alert to persistent throat or mouth symptoms, get vaccinated if eligible, and use at-home screening for the STIs that share transmission routes, like chlamydia, gonorrhea, syphilis, and HIV.
- If I have had oral sex, how likely am I to have oral HPV right now?
- Some exposure is statistically common. CDC surveillance data put oral HPV prevalence at about 10 percent in men and 3.6 percent in women at any given time, with high-risk strains making up a smaller share of those infections. Most of these infections clear within one to two years without symptoms. Even when infection persists, progression to cancer involves only a small fraction of cases; the vast majority of men with long-term oral HPV never develop disease.
- What is the difference between genital HPV and oral HPV?
- Both are caused by the same family of human papillomaviruses, but the location of the infection changes what it can cause. Genital HPV infections are linked to cervical, anal, and penile cancers, plus genital warts from low-risk strains. Oral HPV infections live in the back of the throat and tonsils, where high-risk strains like HPV-16 can drive oropharyngeal cancers years later. The strain types overlap (HPV-16 in particular shows up in both sites), but the infection sites and the cancers they cause are different. A person can have one, the other, both, or neither at any given time.
- What does early HPV-related throat cancer feel like?
- Usually nothing dramatic. The most commonly reported early symptoms are a sore on the tongue or in the mouth that will not heal, persistent hoarseness, a painless lump in the neck, pain when swallowing, or a sense that something is stuck in the throat. None of these confirm cancer on their own; many have benign causes. The rule clinicians use is duration: anything persisting beyond two weeks without improvement deserves an evaluation.
- Is it too late to get the HPV vaccine in my thirties or forties?
- Probably not. The HPV vaccine is approved in the United States for adults aged 27 through 45 under shared clinical decision-making with a provider. It will not eliminate any strain you already carry, but it can protect against high-risk strains you have not yet encountered. Whether it makes sense for any individual depends on prior exposure history, current sexual activity patterns, and cost, which is exactly the kind of conversation that belongs in a clinic visit.
- Do condoms and dental dams prevent oral HPV?
- They reduce risk meaningfully without eliminating it. HPV spreads through skin-to-skin mucosal contact, and barriers only cover part of the area involved during oral sex. Consistent barrier use remains worthwhile as one layer of protection among several, including vaccination, fewer concurrent partners, and routine STI screening.
- How long does it take HPV to cause cancer when it does?
- The window from initial infection to cancer, in the rare cases where one develops, is typically a decade or more, sometimes several decades. Most persistent infections never reach cancer at all. The slow timeline is part of why blame is unhelpful when a diagnosis comes: by the time symptoms appear, the relevant exposure is usually long in the past, and the person it came from may have had no way of knowing they carried it.
- I have a sore throat that will not go away. Should I assume it is HPV cancer?
- No. Most persistent sore throats are caused by viral infections, allergies, acid reflux, post-nasal drip, smoking irritation, or muscle tension. HPV-related cancer is a much rarer cause. The action is the same regardless of which is more likely: if a throat symptom has been present for two weeks without improving, schedule a dentist or primary care visit. The evaluation is straightforward, and ruling out the serious causes is itself useful.
How we sourced this article: This piece builds on reporting from BBC News about a UK father who nearly lost his tongue to HPV-related cancer, and integrates current guidance from the CDC, World Health Organization, Mayo Clinic, Johns Hopkins Medicine, and the American Cancer Society. All claims about HPV prevalence, oropharyngeal cancer rates, vaccine eligibility, and the two-week persistence rule are drawn from the cited public-health sources. This article does not provide personal clinical advice; for persistent symptoms, consult a licensed provider.
- BBC News. Dad who nearly lost tongue to cancer urges men's virus awareness. The original news story that motivated this article.
- U.S. Centers for Disease Control and Prevention. About Genital HPV Infection: prevalence estimates, transmission routes, and clearance behavior for HPV in U.S. adults.
- U.S. Centers for Disease Control and Prevention. HPV and Oropharyngeal Cancer: U.S. incidence data, the 60 to 70 percent attribution range, the 1-to-2-year clearance window, and oral HPV prevalence by sex (about 10 percent in men, 3.6 percent in women).
- U.S. Centers for Disease Control and Prevention. HPV and Cancer: the 'over 90 percent of HPV-attributable cancers preventable by vaccination' figure quoted in the highlight box.
- World Health Organization. Human papillomavirus (HPV) and cervical cancer fact sheet: global prevalence and high-risk-strain context.
- Mayo Clinic. Throat cancer: symptoms and causes, including the persistence rules used in clinical evaluation.
- Johns Hopkins Medicine. Oral cancer overview: clinical signs, risk factors, and diagnostic pathway.
- American Cancer Society. Oral cavity and oropharyngeal cancer: risk factors, screening limitations, and staging context.
